U.S. Professional Services Stock News

With the business potentially at an important milestone, we thought we'd take a closer look at Iterum Therapeutics...

MSCI (NYSE:MSCI) plans to reclassify Greece from Emerging Market to Developed Market status in its equity indexes. The company is also partnering with Syntax Data to expand its ADR index offerings for financial advisers in the US. These changes affect how global capital is allocated to Greek equities and how advisers access international exposure through US listed securities. MSCI is best known for its global equity indexes that many asset managers and ETFs use as benchmarks, so its country...

In March 2026, Signet Jewelers reported fourth-quarter sales of US$2,345.1 million and net income of US$250.0 million, alongside a higher full-year profit, while also raising its quarterly dividend to US$0.35 per share and continuing share repurchases. The sharp year-on-year jump in earnings per share, combined with a nearly double-digit dividend increase and ongoing buybacks, underscores management’s confidence in the company’s financial position and cash-generation capacity. We’ll now...

We can readily understand why investors are attracted to unprofitable companies. For example, Annexon ( NASDAQ:ANNX...

Creative Medical Technology Holdings, Inc. ( NASDAQ:CELZ ) is possibly approaching a major achievement in its business...

Potential LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders may wish to note that the President, Evert...

The market seemed underwhelmed by the solid earnings posted by Adobe Inc. ( NASDAQ:ADBE ) recently. Along with the...

Market forces rained on the parade of MeiraGTx Holdings plc ( NASDAQ:MGTX ) shareholders today, when the analysts...

Volvo Cars has converted its outstanding shareholder loans to Polestar Automotive Holding UK (NasdaqGM:PSNY) into equity, changing the mix of Polestar’s capital structure. The two companies also agreed to concentrate future manufacturing of the Polestar 3 in the U.S., expanding their existing production collaboration. For investors watching NasdaqGM:PSNY, these moves come against a backdrop of a share price at $18.42 and a long term track record that includes a 41.5% decline over the past...

Capital raise potential and what it could mean for XPLR Infrastructure (XIFR) XPLR Infrastructure (XIFR) has filed a US$300 million shelf registration for its common units, giving the partnership flexibility to issue equity as funding needs or investment plans emerge. See our latest analysis for XPLR Infrastructure. The shelf filing comes as XIFR’s share price sits at US$10.62, with a 1 day share price return of 4.94% and a 1 year total shareholder return of 13.83%. The 3 year total...

Alnylam Pharmaceuticals has reported new clinical and real world data on its RNAi therapy vutrisiran in ATTR-CM, highlighting durable benefits in quality of life and reductions in advanced disease progression and mortality. The company has also shared pooled Phase 2 safety data for zilebesiran that supports its move into a global Phase 3 trial in hypertension and cardiovascular risk reduction. For investors tracking NasdaqGS:ALNY, this update centers on the company’s core RNAi franchise and...

UP Fintech Holding Limited recently reported its fourth-quarter and full-year 2025 results, with Q4 revenue of US$175.57 million and net income of US$45.23 million, and full-year revenue of US$612.06 million and net income of US$170.9 million, all higher than the prior year. The sharp rise in basic earnings per share from continuing operations to US$0.96 for 2025, up from US$0.375 a year earlier, highlights a significant improvement in profitability. We will now examine how this strong...

Wondering if National Health Investors is priced fairly today or if the current share price leaves some room on the table? This overview walks through what the recent numbers may be saying about value. The stock closed at US$80.86, with returns of 5.2% year to date and 14.2% over the last year, while the past 7 and 30 days have seen declines of 2.1% and 3.8% respectively. Recent coverage has focused on how real estate investment trusts are responding to changing conditions in healthcare...

Wondering whether GEO Group at around US$16.81 is starting to look like value or a value trap? This breakdown will help you frame the stock in numbers, not noise. The share price has moved around recently, with a 0.8% decline over the past week, an 11.8% gain over 30 days, a 5.5% return year to date and a 43.8% decline over the last year, set against a 113.9% return over 3 years and 115.5% over 5 years. Recent attention on GEO Group has focused on its role in private corrections and...

In late March 2026, MKS Inc. disclosed that it had received a shareholder proposal from John Chevedden seeking the right for shareholders holding a specified ownership threshold to call special shareholder meetings, and the board urged investors to vote against it at the upcoming May 11, 2026 annual meeting. This governance dispute highlights a tension between management’s preferred control over the corporate agenda and some investors’ desire for more flexible shareholder rights. Next, we...

Sangamo Therapeutics (SGMO) closed out FY 2025 with Q4 revenue of US$14.2 million and a basic EPS loss of US$0.11, as net income excluding extra items came in at a loss of US$37.4 million. On a trailing twelve month basis, revenue was US$39.6 million with a basic EPS loss of US$0.44 and a net loss of US$122.9 million. The company has seen quarterly revenue range from US$0.6 million to US$49.4 million across the last six reported periods, with basic EPS moving between a loss of US$0.14 and a...

In recent days, Global-E Online has seen heavy selling ease as the stock reached technically oversold levels, coinciding with Wall Street analysts revising their earnings estimates higher and awarding it a Zacks Rank #1 (Strong Buy) rating. This combination of improving earnings expectations and oversold technical conditions highlights how sentiment can shift quickly when fundamentals and trading signals align for Global-E. Next, we’ll examine how this wave of upward earnings estimate...

DeFi Development (DFDV) just wrapped up FY 2025 with Q4 total revenue of US$4.5 million and a basic EPS loss of US$5.48, while trailing twelve month revenue sat at US$11.4 million against a basic EPS loss of US$4.00. Over the past six reported quarters, the company has seen quarterly revenue move from US$0.62 million in Q4 2024 to US$4.5 million in Q4 2025, with EPS swinging between a loss of US$0.05 and a profit of US$2.41 before landing back in loss-making territory. This leaves investors...

Tilray Brands (TLRY) is back in focus after fresh product launches in its beverage portfolio and the approach of its Q3 2026 earnings release and earnings call scheduled for April 1. See our latest analysis for Tilray Brands. Despite the fresh Popsicle Hard and Shock Top High Voltage launches and attention around the upcoming Q3 update, Tilray Brands’ recent share price returns point to fading momentum, with a 30 day share price return of a 17.79% decline and a 3 year total shareholder return...

Rezolve AI (RZLV) has just put fresh FY 2025 numbers on the table, with second half revenue of about US$40.5 million and a basic EPS loss of US$0.14, backed by trailing twelve month revenue of roughly US$46.8 million and a basic EPS loss of US$0.38. The company has seen revenue move from just US$0.1 million in the second half of FY 2024 to US$6.3 million in the first half of FY 2025 and then to US$40.5 million in the latest half, while basic EPS losses shifted from US$0.98 to US$0.25 and then...

If you are wondering whether Buckle at around US$50.36 offers solid value or is pricing in too much optimism, this breakdown will help you frame that question clearly. The stock has had a mixed short term patch, with a 0.6% return over the last week, a 6.0% decline over the past month, and a 6.5% decline year to date, as well as a 42.9% return over the last year and 84.3% and 112.4% returns over the past 3 and 5 years. Recent coverage has focused on Buckle in the context of broader retail...

Kodiak Sciences (KOD) is back in focus after reporting that its GLOW2 Phase 3 study of Zenkuda in diabetic retinopathy met key efficacy and safety endpoints, supporting a multi-indication, BLA-ready profile. See our latest analysis for Kodiak Sciences. The Zenkuda update arrives alongside sharp recent moves in the stock, with a 74.46% 7 day share price return and a 42.24% 30 day share price return. The 1 year total shareholder return is very large, suggesting momentum has picked up sharply...

First Keystone (FKYS) just wrapped up FY 2025 with fourth quarter revenue of US$7.8 million and a basic EPS loss of US$0.10, while the trailing twelve months show total revenue of US$40.3 million and EPS of US$0.99. Over recent periods the company has seen quarterly revenue move from US$10.4 million in Q4 2024 to US$11.5 million in Q2 2025 before landing at US$7.8 million in Q4 2025, with basic EPS shifting from US$0.37 in Q4 2024 to US$0.47 in Q2 2025 before slipping into a small loss in the...

Allison Transmission Holdings (NYSE:ALSN) is acquiring Dana’s Off-Highway business, expanding its reach beyond on-highway applications. The deal adds exposure to off-highway markets such as construction, agriculture and mining, widening Allison’s addressable customer base. Investors now have new information to assess Allison’s mix of end markets, revenue sources and integration priorities. Allison Transmission Holdings, trading at $117.06, has seen its share price rise 18.3% year to date...